We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+3.13%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.45B
AUM Growth
-$170M
Cap. Flow
+$90.1M
Cap. Flow %
6.21%
Top 10 Hldgs %
63.01%
Holding
41
New
5
Increased
1
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
EPC icon
Edgewell Personal Care
EPC
+$239M
2
AVBP icon
ArriVent BioPharma
AVBP
+$21.7M
3
VRDN icon
Viridian Therapeutics
VRDN
+$21.3M
4
MGX icon
Metagenomi Therapeutics
MGX
+$20M
5
KYTX icon
Kyverna Therapeutics
KYTX
+$19.5M

Top Sells

Rank Stock Value
1
TSM icon
TSMC
TSM
+$73.9M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$66.4M
3
CBAY
Cymabay Therapeutics
CBAY
+$21.3M
4
SPRB
Spruce Biosciences
SPRB
+$19.7M
5
CRM icon
Salesforce
CRM
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 45.12%
2 Technology 24.54%
3 Financials 13.03%
4 Consumer Staples 7.98%
5 Communication Services 3.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGX icon
26
Metagenomi Therapeutics
MGX
$46.3M
$18.3M 1.27%
+1,739,175
New +$20M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$29.3B
$17.7M 1.22%
118,383
– –
KYTX icon
28
Kyverna Therapeutics
KYTX
$484M
$17.4M 1.2%
+700,000
New +$19.5M
INSP icon
29
Inspire Medical Systems
INSP
$1.74B
$14.1M 0.97%
65,524
– –
IOBT
30
DELISTED
IO Biotech
IOBT
$8.8M 0.61%
5,088,258
-658,809
-11% -$1.14M
ABCL icon
31
AbCellera Biologics
ABCL
$2.12B
$5.1M 0.35%
1,126,915
– –
TMCI icon
32
Treace Medical Concepts
TMCI
$309M
$4.7M 0.32%
360,000
– –
MQ icon
33
Marqeta
MQ
$1.66B
$2.63M 0.18%
110,390
– –
DMRA
34
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.84B
$1.95M 0.13%
99,912
– –
SPRO icon
35
Spero Therapeutics
SPRO
$73M
$807K 0.06%
468,902
– –
EWTX icon
36
Edgewise Therapeutics
EWTX
$4.73B
– –
-6,071,703
Closed -$66.4M
LVTX
37
DELISTED
LAVA Therapeutics
LVTX
– –
-1,878,194
Closed -$2.97M
RLYB icon
38
Rallybio
RLYB
$85.8M
– –
-220,983
Closed -$4.23M
TSM icon
39
TSMC
TSM
$2.18T
– –
-710,780
Closed -$73.9M
SPRB
40
Spruce Biosciences
SPRB
$129M
– –
-89,631
Closed -$19.7M
CBAY
41
DELISTED
Cymabay Therapeutics
CBAY
– –
-900,000
Closed -$21.3M
1
2

Similar funds

MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.24B AUM 16.52% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return
SPC
Stony Point Capital New York $1.24B AUM 32.69% 1-Year Est. Return
SC
Strategy Capital Los Altos, California $1.22B AUM 27.02% 1-Year Est. Return

Novo Holdings A/S's Q1 2024 Portfolio in Review

As of Q1 2024, Novo Holdings A/S held 41 positions worth $1.45B, down 10% from $1.62B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Novo Holdings A/S deployed $90.1M of net new capital in Q1 2024, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Edgewell Personal Care: 6,344,430 shares worth $116M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 52% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Salesforce, an estimated $14.5M trimmed.

  • Novo Holdings A/S's largest Q1 2024 buy was Edgewell Personal Care: 6,344,430 shares worth $116M.
  • Novo Holdings A/S added most to Lexeo Therapeutics in Q1 2024, an estimated $5.17M increase.
  • Novo Holdings A/S's biggest Q1 2024 reduction was Salesforce, cutting an estimated $14.5M.
  • Novo Holdings A/S fully exited TSMC in Q1 2024, selling an estimated $73.9M.
  • Novo Holdings A/S's ten largest holdings make up 63% of its $1.45B portfolio in Q1 2024.
  • Novo Holdings A/S opened 5 new positions and closed 6 in Q1 2024.
  • Novo Holdings A/S's portfolio value fell 10% quarter-over-quarter to $1.45B.

Based on Novo Holdings A/S's 13F filing for Q1 2024, filed 15 May 2024.